Goldman Sachs Group Inc Ab Cellera Biologics Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 218,725 shares of ABCL stock, worth $1.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

218,725

Previous 86,483 152.91%

Holding current value

$1.28 Million

Previous $192,000 290.63%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.93 - $3.8 $255,227 - $502,519	132,242 Added 152.91%	218,725 $750,000
Q1 2025 May 09, 2025	SELL	$2.2 - $3.53 $469,326 - $753,054	-213,330 Reduced 71.15%	86,483 $192,000
Q4 2024 Feb 11, 2025	BUY	$2.48 - $3.15 $233,382 - $296,433	94,106 Added 45.75%	299,813 $878,000
Q3 2024 Nov 14, 2024	BUY	$2.39 - $3.49 $262,754 - $383,687	109,939 Added 114.8%	205,707 $532,000
Q2 2024 Aug 13, 2024	SELL	$2.73 - $4.73 $302,099 - $523,417	-110,659 Reduced 53.61%	95,768 $283,000
Q1 2024 May 15, 2024	SELL	$4.29 - $5.97 $1.69 Million - $2.36 Million	-394,814 Reduced 65.67%	206,427 $935,000
Q4 2023 Feb 13, 2024	BUY	$3.91 - $5.93 $1.34 Million - $2.03 Million	341,945 Added 131.87%	601,241 $3.43 Million
Q3 2023 May 14, 2024	SELL	$4.6 - $7.95 $1.57 Million - $2.72 Million	-341,945 Reduced 56.87%	259,296 $1.19 Million
Q3 2023 Nov 14, 2023	SELL	$4.6 - $7.95 $740,512 - $1.28 Million	-160,981 Reduced 38.3%	259,296 $1.19 Million
Q2 2023 May 14, 2024	BUY	$5.66 - $7.59 $390,149 - $523,186	68,931 Added 19.62%	420,277 $2.71 Million
Q2 2023 Aug 14, 2023	BUY	$5.66 - $7.59 $390,149 - $523,186	68,931 Added 19.62%	420,277 $2.71 Million
Q1 2023 May 14, 2024	SELL	$7.31 - $11.18 $829,904 - $1.27 Million	-113,530 Reduced 24.42%	351,346 $2.65 Million
Q1 2023 May 11, 2023	SELL	$7.31 - $11.18 $829,904 - $1.27 Million	-113,530 Reduced 24.42%	351,346 $2.65 Million
Q4 2022 May 14, 2024	BUY	$9.48 - $14.52 $603,487 - $924,328	63,659 Added 15.87%	464,876 $4.71 Million
Q4 2022 Feb 13, 2023	BUY	$9.48 - $14.52 $603,487 - $924,328	63,659 Added 15.87%	464,876 $4.71 Million
Q3 2022 May 14, 2024	BUY	$9.2 - $13.68 $1.53 Million - $2.28 Million	166,730 Added 71.1%	401,217 $3.97 Million
Q3 2022 Nov 10, 2022	BUY	$9.2 - $13.68 $1.53 Million - $2.28 Million	166,730 Added 71.1%	401,217 $3.97 Million
Q2 2022 May 14, 2024	SELL	$5.72 - $10.65 $2.1 Million - $3.91 Million	-366,754 Reduced 61.0%	234,487 $2.5 Million
Q2 2022 Aug 15, 2022	BUY	$5.72 - $10.65 $696,478 - $1.3 Million	121,762 Added 108.02%	234,487 $2.5 Million
Q1 2022 May 16, 2022	SELL	$7.46 - $14.14 $169,521 - $321,317	-22,724 Reduced 16.78%	112,725 $1.1 Million
Q4 2021 Feb 14, 2022	BUY	$12.99 - $17.73 $1.52 Million - $2.07 Million	116,704 Added 622.59%	135,449 $1.94 Million
Q3 2021 Nov 10, 2021	BUY	$14.85 - $21.34 $278,363 - $400,018	18,745 New	18,745 $376,000

Others Institutions Holding ABCL

# of Institutions

150

Shares Held

114M

Call Options Held

488K

Put Options Held

476K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $1.67B
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Ab Cellera Biologics Inc. Transaction History